Spots Global Cancer Trial Database for Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma

Official Title: Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma-A Retrospective Study

Study ID: NCT05024539

Conditions

Hepatocellular Carcinoma

Interventions

nonintervention

Study Description

Brief Summary: Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma

Detailed Description: To analyze the real-world usage pattern, effectiveness and factors associated with the effectiveness of regorafenib in the treatment of patients with Hepatocellular Carcinoma. This retrospective, observational study included clinicopathological and follow-up data of patients with Hepatocellular Carcinoma who were treated with regorafenib from June 2017 to September 2020. Patients with incomplete data were excluded. Overall survival (OS) stratified by combination therapy with programmed cell death ligand-1 (PD-L1) inhibitors, chemotherapy and regorafenib dose was calculated by Kaplan Meier method and log rank test. R software version 4.0 was used for the analysis.